On November 23, 2021 SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, reported that management will participate in a Fireside Chat at the 4th Annual Evercore ISI HealthCONx Conference, taking place virtually on Tuesday, November 30, 2021, at 3:30 pm ET (Press release, SpringWorks Therapeutics, NOV 23, 2021, View Source [SID1234595975]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A video webcast will be available on the Events & Presentations page within the Investors & Media section of the company’s website at View Source A replay of the webcast will be available on SpringWorks’ website for a limited time following the conference.

On November 23, 2021 Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications including ocular and urologic cancers, reported that Elisabet de los Pinos, Chief Executive Officer of Aura, will participate in a fireside chat at the 4th Annual Evercore ISI HealthCONx conference taking place on Tuesday, November 30, 2021 at 2:15 p.m. Eastern Time (Press release, Aura Biosciences, NOV 23, 2021, View Source [SID1234595993]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat will be available on the "Investors & Media" page under the "Events & Presentations" section of the Company’s website at View Source, where a replay of the webcast will be archived for 90 days following the presentation date.

On November 23, 2021 KYAN Therapeutics Inc., a biotech company focused on improved cancer treatment outcomes, reported that data from clinical feasibility studies conducted by the National University of Singapore and Singapore’s National University Hospital will be presented at the 63rd American Society of Hematology (ASH) (Free ASH Whitepaper) annual meeting, to be held in Atlanta, Georgia and virtually on December 11-14, 2021 (Press release, KYAN Therapeutics, NOV 23, 2021, View Source [SID1234632305]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The studies demonstrated the clinical application of a personalized combination treatment platform for relapsed and refractory non-Hodgkin lymphoma patients. KYAN will be working with clinical collaborators in Singapore to conduct a Phase 2 clinical trial to evaluate this technology for personalized combination treatments in refractory T-cell lymphoma.

Details related to the oral presentations are as follows:

Title: Clinical Application of an Ex-Vivo Platform to Guide the Choice of Drug Combinations in Relapsed/Refractory Lymphoma; A Prospective Study

Presenting Author: Sanjay De Mel, National University Cancer Institute Singapore

Abstract Number: 720

Session Name: 622. Lymphomas: Translational–Non-Genetic: Lymphoma biology Hematology Disease Topics & Pathways: Translational Research, Lymphomas, Diseases, Lymphoid Malignancies

Session Date: Monday, December 13, 2021

Session Time: 2:45 PM-4:15 PM

Presentation Time: 4:00 PM

On November 23, 2021 Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics for the treatment of cancer and autoimmune diseases, reported that Pablo J. Cagnoni, M.D., President and Chief Executive Officer, will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Conference on November 30, 2021, at 10:55 a.m. EST (Press release, Rubius Therapeutics, NOV 23, 2021, View Source [SID1234595959]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast will be available within the Investors & Media section of the Rubius Therapeutics website. An archived replay will be accessible for 90 days following the event.

On November 23, 2021 Immunomic Therapeutics, Inc., ("ITI") a privately held clinical-stage biotechnology company focused on advancing its proprietary nucleic acid immunotherapy platform, reported an exclusive option to license or acquire a series of innovative technologies in the immuno-oncology space from iOncologi, Inc., ("iOi") (Press release, Immunomic Therapeutics, NOV 23, 2021, View Source [SID1234595977]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Preclinical studies led by iOi Co-Founders, Drs. Duane Mitchell and Catherine Flores, have demonstrated that resistance to immune checkpoint inhibitors (ICIs) can be overcome by iOi’s novel, intravenously delivered stem cell-based therapeutic. Rapid translation of this possible breakthrough discovery into first-in-human clinical trials is underway. ITI’s option offers potential opportunities for both companies to further facilitate clinical and commercial development in the field of cell therapy and for collaboration in the development of nucleic acid vaccines that complements ITI’s own UNITE technology. The option agreement contemplates additional investment by ITI dependent upon iOi achieving certain clinical trial milestones.

"We are pleased to expand our collaboration with Dr. Duane Mitchell, both in his role as Founder & President of iOncologi, and as a leading academic researcher in the immuno-oncology field. Dr. Mitchell has been instrumental in the development and leadership of our ATTAC-II clinical trial for patients with Glioblastoma," said Dr. William Hearl, CEO of Immunomic Therapeutics. "His determination to bring innovative treatments to patients is what compounds the complementary technologies in both companies."

"We are very excited to have iOncologi and Immunomic Therapeutics bring together complementary expertise in the advancement of new treatments for patients with refractory cancers," said Dr. Mitchell. "This agreement expands upon a longstanding and very fruitful collaboration with Dr. Hearl and the team at ITI in bringing forward novel immunotherapy treatments for patients with Glioblastoma. I look forward to the advances that will come from this agreement between the two companies."